Published by Global Banking & Finance Review®
Posted on February 28, 2025
1 min readLast updated: January 25, 2026
Add as preferred source on Google
The UK MHRA has approved Moderna's RSV vaccine, mRESVIA, for adults 60+, aiming to prevent severe respiratory infections.
(Reuters) - Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 years and older.
The shot, branded as mRESVIA, is for the prevention of lower respiratory tract disease in older adults, the Medicines and Healthcare products Regulatory Agency (MHRA) said.
RSV is a common virus that spreads very easily and causes infections that can be mild, with cold-like symptoms, but can also cause more serious problems, such as lung infections and pneumonia.
Older adults are at risk of more serious complications that could lead to hospital admission and even death.
GSK's vaccine Arexvy and Pfizer's <PFE.N> shot Abrysvo are approved for use in individuals over the age of 60 in the UK.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar and Shailesh Kuber)
The vaccine is approved for adults aged 60 years and older.
The mRESVIA vaccine is designed to prevent lower respiratory tract disease in older adults.
Older adults are at risk of serious complications from RSV that could lead to hospital admission and even death.
GSK's vaccine Arexvy and Pfizer's shot Abrysvo are also approved for individuals over the age of 60 in the UK.
Explore more articles in the Headlines category
